Changes to This Summary (02/19/2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Adult Non-Hodgkin Lymphoma (NHL)

Updated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 2).

Indolent NHL

Added text to state that follicular lymphoma in situ and primary follicular lymphoma of the duodenum are particularly indolent variants that rarely progress and rarely require therapy (cited Schmatz et al. and Jegalian et al. as references 17 and 18, respectively).

Revised text to state that myeloablative therapy with autologous or allogeneic hematopoietic stem cell support is under clinical evaluation (cited Kyriakou et al. as reference 48).

Added Nakamura et al. as reference 62.

Added Kempf et al. as reference 97.

Aggressive NHL

Added Glantz et al. as reference 18.

Added text to state that similar response rates in relapsing patients were seen for the histone deacetylase inhibitor ramidepsin for 130 evaluable patients in a prospective trial (cited Coiffler et al. as reference 70).

Added Di Sabatino et al. as reference 87.

Added Bazarbachi et al. as reference 125.

Added Griffiths et al. as reference 143.

Added LaCasce et al. as reference 144.

Stage Information for Adult NHL

Revised text to state that interim positive emission tomography (PET) scans after two to four cycles of therapy did not provide reliable prognostic information because of problems of interobserver reproducibility in a large cooperative group trial, ECOG-E3444, and lack of difference in outcome between PET-negative and PET-positive/biopsy-negative patients in two prospective trials (cited Pregno et al. as reference 9).

Added Salles et al. and Advani et al. as references 13 and 14, respectively.

Treatment for Indolent, Stage I and Contiguous Stage II Adult NHL

Added Kelsey et al. and Seymour et al. as references 6 and 7, respectively.

Treatment for Indolent, Noncontiguous Stage II/III/IV Adult NHL

Revised text to state that rituximab may be considered as first-line therapy, either alone or in combination with other agents.

Added text to state that in a meta-analysis of 2,586 patients with follicular lymphoma, nine randomized clinical trials compared rituximab maintenance with no maintenance and showed improved overall survival (OS) for rituximab maintenance in previously treated patients (cited Vidal et al. as reference 56 and level of evidence: 1iiA).

Added Al Khabori et al. as reference 66.

Added text to the list of treatment options under clinical evaluation to include ofatumumab, a human anti-CD20 monoclonal antibody (cited Czuczman et al. as reference 71) and short-course low-dose, palliative radiation therapy (cited Chan et al. and Rossier et al. as references 72 and 73, respectively).

Treatment for Aggressive, Stage I and Contiguous Stage II Adult NHL

Revised text to state that with a median follow-up of 72 months, the event-free survival favored R-CHOP given every 2 weeks for six or eight cycles. Also revised statistics about OS favoring R-CHOP for only six cycles because of increased toxicity in the eight-cycle arm (cited Pfreundschuh et al. as reference 8).

Treatment for Aggressive, Noncontiguous Stage II/III/IV Adult NHL

Added text to state that a trial of 380 patients younger than 60 years with diffuse large B-cell lymphoma and an age-adjusted International Prognostic Index rating of 1 randomized treatment to ACVBP + rituximab versus CHOP + rituximab; with a median follow-up of 44 months, 3-year OS favored R-ACVBP (cited Récher et al. as reference 7 and level of evidence: 1iiA).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.